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Epithelial NFB Mediates T Cell-Induced
Diarrhea
Innate and adaptive immune responses contribute to
mucosal permeability and diarrhea in inflammatory bowel
disease (IBD); however, the mechanisms that govern this
response are not completely understood. Tang et al,
Am J Pathol (2009), 175:158–167, therefore examined
the role of nuclear factor B (NF-B), an inflammatory
mediator, in IBD-induced permeability enhancement in a
model of epithelial-specific repression of NF-B activity.
Following T cell-mediated immune activation, epithelial-
specific NF-B repression inhibited diarrhea and pre-
vented internalization of tight junction proteins, which
decreased paracellular permeability. These findings sug-
gest that T cell-mediated activation of NF-B in IBD pro-
motes the movement of fluid into the bowel lumen, result-
ing in diarrhea.
Attenuated Plasmodium Generates Protective
Immunity
Plasmepsin 4 is an aspartic protease that contributes to
hemoglobin digestion, which is critical for Plasmodium
growth and survival within the host erythrocyte. Spac-
capelo et al, Am J Pathol (2009), 175:205–217, therefore
examined plasmepsin 4-null Plasmodium parasites for
deficiencies in parasite growth and virulence. Although
there was only a modest effect of plasmepsin 4 defi-
ciency on Plasmodium growth and development within
erythrocytes, plasmepsin 4-null parasites were signifi-
cantly less virulent than their wild-type counterparts. In-
fection with plasmepsin 4-deficient parasites, in con-
trast to infection with wild-type Plasmodium, did not
induce cerebral complications. Furthermore, plasmep-
sin 4-null Plasmodium induced strong protective im-
mune responses against secondary immunization with
wild-type Plasmodium. Virulence-attenuated Plasmo-
dium may therefore provide a model for assessing
genetically attenuated malarial vaccine candidates.
Osteopontin Contributes to Allergic Contact
Dermatitis
Allergic contact dermatitis is a T-cell-mediated immune
response to environmental allergens that contact the
skin. Seier et al, Am J Pathol (2009), 175:246–258, hy-
pothesized that osteopontin (OPN), an immune mediator
that has been shown to exacerbate autoimmune disease,
plays a role in eliciting and facilitating chronic allergic
contact dermatitis. They found that both keratinocytes
and T cells secreted OPN in allergic contact dermatitis
lesions. OPN was strongly induced in antigen-specific T
cells in a murine model of chronic contact hypersensitiv-
ity, and OPN-deficient mice had a less severe chronic
contact hypersensitivity response. As anti-OPN antibody
treatment partially suppressed the symptoms of chronic
contact hypersensitivity, OPN may serve as a new ther-
apeutic target for allergic contact dermatitis.
Vascular Pathology in Familial Alzheimer
Disease
Presenilin-1 (PS-1; PSEN1) is a component of the
-secretase protease complex, which cleaves amyloid
precursor protein, producing amyloid . Mutations in
PSEN1 are the most commonly known cause of familial
Alzheimer disease (FAD). To determine whether mutated
PS-1 contributes to the vascular pathology observed in
FAD, Gama Sosa et al, Am J Pathol (2009), 175:353–368,
generated a mouse model that overexpressed either wild-
type or mutated human PS-1. They found age-related vas-
cular pathology in these FAD model mice that was espe-
cially prominent in themicrovasculature. However, the basis
for this pathology appears to lie in the neurons, vascular
endothelial and glial cells do not express PS-1 in these
mice. Taken together, these results implicate a role for
neuronal to vascular signaling in the pathogenesis of vas-
cular pathology in FAD.
Prostate Cancer Survival via Mitochondrial
TRAP-1
TNF-receptor-associated protein-1 (TRAP-1), a mito-
chondrial heat shock protein chaperone, may regulate
mitochondrial membrane permeability and thus apopto-
sis. Leav et al, Am J Pathol (2009), 175:393–401, ex-
plored the role of TRAP-1 in prostate cancer survival.
TRAP-1 was highly expressed in both high-grade human
prostate cancer lesions and mouse models of prostate can-
cer but not in benign or normal prostate tissue. TRAP-1
overexpression in non-cancer prostate cells inhibited cell
death, and TRAP-1-deficient prostate cancer cells had en-
hanced levels of apoptosis. Moreover, treatment with Gami-
trinib, which inhibits TRAP-1, resulted in the death of pros-
tate cancer cells, but not of non-cancerous prostate cells.
Therefore, targeting TRAP-1 via Gamitrinib treatment may
be a viable therapeutic strategy for patients with advanced
prostate cancer.
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